Eective anti cancer strategies necessitate the use of agents that target tumor cells rather than normal tissues. In this study, we constructed a tumor-selective adenovirus, D24, that carries a 24-bp deletion in the E1A region responsible for binding Rb protein. Immunoprecipitation analyses veri®ed that this deletion rendered D24 unable to bind the Rb protein. However, titration experiments in 293 cells demonstrated that the D24 adenovirus could replicate in and lyse cancer cells with great eciency. Lysis of most human glioma cells was observed within 10 ± 14 days after infection with D24 at 10 PFU/cell. In vivo, a single dose of the D24 virus induced a 66.3% inhibition (P50.005) and multiple injections, an 83.8% inhibition (P50.01) of tumor growth in nude mice. However, normal ®broblasts or cancer cells with restored Rb activity were resistant to the D24 adenovirus. These results suggest that the E1A-mutant D24 adenovirus may be clinically and therapeutically useful against gliomas and possibly other cancers with disrupted Rb pathway. Oncogene (2000) 19, 2 ± 12.
Introduction
The properties of adenoviruses to rely on host cells for their own propagation can be utilized to obtain antineoplastic eects on human tumors. In this regard, adenoviruses synthesize proteins that compel infected cells to replicate the viral DNA. The E1A proteins are the ®rst virus-speci®c polypeptides synthesized after adenoviral infection, and are required for viral replication to occur (Dyson and Harlow, 1992; Flint and Shenk, 1997) . The targets of E1A proteins, such as Rb, seem to modulate the cell cycle by regulating cell progression from G0 and G1 into S phase. In the case of Rb, binding between the Rb protein and the E1A proteins results in release of E2F from preexisting cellular E2F-Rb complexes. The E2F is then free to activate both the E2 promoter of the adenovirus and several cell cycle-regulatory genes. The transcriptional activation of these cellular genes in turn helps to create an environment suitable for viral DNA synthesis in otherwise quiescent cells (Nevins, 1992) . Two segments of E1A are important for binding Rb; one includes amino acids 30 ± 60 and the other amino acids 120 ± 127 (Whyte et al., 1988 (Whyte et al., , 1989 . Deletion of either region prevented the formation of detectable E1A/Rb complexes in vitro and in vivo (Whyte et al., 1989) . In the present study, we used these observations to develope a mutant adenovirus which encodes a E1A protein with deletion of amino acids 120 ± 127 that selectively targets cells with abnormal Rb control.
Targeting the Rb pathway is important in treating gliomas because abnormalities of the p16/Rb/E2F pathway are present in most gliomas (Fueyo et al., 1998a; Gomez-Manzano et al., 1998) . Targeting this pathway by replacing of lost tumor suppressor activity through the transfer of p16 and Rb genes has produced cytostatic eects (Fueyo et al., 1998a; Gomez-Manzano et al., 1998) . Transfer of E2F-1 resulted in powerful anti-cancer eect since the exogenous wild-type E2F-1 induced apoptosis and inhibited tumor growth in vivo (Fueyo et al., 1998b) . However, treating human glioma tumors with these adenovirus constructs realistically cannot aect signi®cant portions of the tumor, mainly because replication-de®cient adenoviral vectors are unable to transfer the exogenous gene to sucient numbers of cancer cells (Puumalainen et al., 1998) . Thus, although targeting the p16/Rb/E2F pathway produces an anti-cancer eect in vitro, this imperfection of the vector system limits the therapeutic eect of the gene in vivo. To overcome these diculties, we combined the selectivity of the anti-cancer eect with a better delivery system in constructing a mutant adenovirus with a deletion of eight amino acids in the Rb-binding region of the E1A protein. We hypothesized that this mutant virus would be selective for tumors because most normal brain cells are arrested in G0, which halts the replication of the mutant adenovirus. However, this adenovirus would also be able to replicate in cancer cells that have disrupted Rb function. Thus, this virus would kill target cells, and amplify and spread the eect from cell to cell within the tumor, but not the surrounding dierentiated cells. produce a stop codon, and the D24 could express a mutant E1A protein (Figure 1 ), this suggested that the mutant adenovirus can replicate. Immunoprecipitation experiments con®rmed however that the mutant E1A protein could not form complexes with the Rb protein (Whyte et al., 1988 (Whyte et al., , 1989 (Figure 1 ).
The infectivity of the adenovirus has been previously tested in a variety of glioma and sarcoma cell lines that have disruptions in the p16/Rb pathway (Fueyo et al., 1996a (Fueyo et al., , 1998c ). The D24 adenovirus had similar eects on the viability of U-251 MG, D-54 MG, U-87 MG, U-373 glioma cells and Saos-2 osteosarcoma cells. Thus, treating any of these cells with the mutant adenovirus at a multiplicity of the infection (MOI) of ten produced complete monolayer cytolysis (85% or more) within 14 days, with most of the glioma cell lines, and the Saos-2 osteosarcoma line, showing cytopathic eect within 7 days. These results were con®rmed by both Trypan blue and crystal violet viability assays (Figure 2 ). Dose-dependence experiments revealed that ®ve MOIs of the D24 adenovirus were enough to induce a noticeable cytopathic eect (Figure 2 ), although the timing and intensity of the oncolytic eect varied slightly among the cell lines tested. For example, by 7 days after treatment with ®ve MOI of D24 adenovirus the oncolytic eect was complete in U-251-MG. In contrast, D-54 MG cells required 10 MOI to obtain a complete monolayer lysis, and U-87 MG cells required ®ve MOI and 14 days of infection.
The replication of D24 is responsible for the anti-cancer eect
Since wild-type adenoviruses can infect and lyse quiescent ®broblasts (Bischo et al., 1996; Heise et al., 1997; Rothman et al., 1998; Hay et al., 1999) , we were interested to ascertain whether the D24 had lost its ability to replicate in and kill normal cells. For these experiments CCD32-Lu lung ®broblasts were arrested in G1 phase after seeded at a low density of 5610 3 cells per well in six-well plates, and cultured with medium plus 1% serum, and infected with ten plaqueforming units (PFU) per cell (the maximum dose used to treat cancer cells) of D24 or UV-D24 (control) adenovirus. Eight days after the infection no differences were found in the numbers of D24-and controlinfected cells (3.3610 3 +0.11; 2.5610 3 +0.07, respectively). Moreover, D24 infection did not result in changes in the morphology of ®broblasts (Figure 3) . These results did not re¯ect an inability of the adenovirus to infect normal cells because these lung ®broblasts could be infected with 50 MOI (470% of the cells) of Ad5CMV-GFP ( Figure 3) . Next, we infected U-251 MG and U-373 MG cells plated at 5610 3 cells per well in six-well plates and cultured with medium plus 1% serum, with ten PFU/cell of D24 or UV-D24 adenovirus. Seven days after the infection, we observed a massive cytopathic eect, with a 94.5+4.6% and 90.1+4.1% decrease in viability of D24-infected-U-251 MG and U-373 MG glioma cells, respectively, with respect to the UV-D24-infected cells. To con®rm that the D24 adenovirus has dierent eects on the viability of normal and cancer cells, we next performed replication assays in which 293 cells were incubated with cell lysates of either normal or Detection of the E1A protein by Western blotting. Twenty-four hours after infection, total protein from U-251 MG cells infected with Ad5CMV-pA, dl1520, or D24 at a dose of 100 MOI, were analysed with anti-E1A antibody as described in Materials and methods. (c) Immunoprecipitation of E1A/host protein complexes. Total lysates from U-251 MG cells infected with D24, dl1520, or Ad5CMV-pA at a dose of 100 MOI were immunoprecipitated using an antibody agarose-conjugated anti-E1A cancer cells. To obtain the cell lysates from either CCD32-Lu, D-54 MG or U-251 MG cells were plated at the same density (10 4 cells per well in six-well plate), infected with one MOIs of either the D24 or the UV-D24 adenovirus, and allowed to grow for 6 days. As soon as 2 days after the infection with D-54 MG or U-251 MG cell lysates, 293 cells showed destruction of the monolayer cultures (Figure 4) . In contrast, 293 cell did not die when the lysates were from normal cells (Figure 4) . These results suggested that the D24 produced progeny virus more eciently in cancer cells than in normal cells.
Next we used plaque assays to quantify the cytopathic eect in terms of viral titers. Virus yields were determined by titer in 293 cells at 6 days after the infection of D-54 MG, U-251 MG and CCD32-Lu with one MOI of either the D24 adenovirus or the UV-D24 control adenovirus. The D24 titer was 60 and 80 times higher than the initial dose in two independent experiments with the D-54 MG lysates and 200 and 400 times higher in the U-251 MG lysate experiments. By contrast, the initial titer did not increase when the lysates were from CCD32-Lu cells ( Figure 4 ). The UV-D24 infected cells did not induce production of new virus. The dierences in the viral titers observed in the experiments with D-54 MG and U-251 MG agreed with the dierences in cytopathic eect observed in the crystal violet assays. These experiments showed that the D24 adenovirus replicated eciently in glioma cells and that normal ®broblasts restricted the spread of the D24.
Transfer of Rb restricts the D24-adenovirus mediated cytolysis
To further con®rm the hypothesis that the D24 adenovirus replicates in a cell cycle restricted manner when the Rb pathway is functionally normal, we next evaluated the ability of the mutant adenovirus to replicate in cells arrested and expressing wild-type Rb. For these experiments we used the osteosarcoma cell line Saos-2, which has a well-characterized disruption of the Rb pathway (Huang et al., 1988) can be easily infected with adenovirus (Fueyo et al., 1998c) , and has a well-characterized response to the transfer of an exogenous Rb (Huang et al., 1988; Fueyo et al., 1998c) . Saos-2 cells were infected with 100 MOI of an adenoviral vector carrying the exogenous wild-type Rb cDNA, or the Ad5CMV-pA adenovirus, and 72 h later were infected with ten MOIs of either the D24 or the UV-D24 adenovirus. As expected, cells that had been pretreated with a vector control, Ad5CMV-pA, were sensitive to the lytic eect of the D24 adenovirus with a complete cytopathic eect (90.5+2.6% decrease in viability) observed within 5 days after the viral infection. By contrast, cells infected with the Ad5CMV-Rb acquired an oncolytic-resistant phenotype with an 88.7+3.1% increase in viability, that persisted for at least 10 days after infection with the D24 adenovirus ( Figure 5 ).
Since, the eect of D24 is theoretically restricted by cell cycle factors, we monitored the changes in the cell cycle pro®le of Saos-2 cells in parallel with the experiments described above. Saos-2 cells infected with the Ad5CMV-Rb were arrested in G1 phase by the third day after infection (77.2+3% of Rb-infected cells versus 59.7+3% of control-infected cells). The (6100) ments. These results suggest that restoration of Rb rendered D24 unable to induce eciently entry of cells into S phase, and therefore precluding viral replication.
To further con®rm the virus-suppressive eect of the Rb protein, we next examined the ability of the cyclindependent-kinase inhibitor p21, a regulator of Rb Normal lung ®broblasts and D-54 MG and U-251 MG glioma cells were seeded at 10 4 cells per well in six-well plates and cultured with medium with 1% fetal bovine serum for 24 h and then infected with one PFU/cell of D24 adenovirus (empty bar). Six days after infection, the virus was released from the cells by three freeze/thaw cycles, and the resulting supernatant was titered on 293 cells. Virus yields are expressed as PFU/ ml. Shown are the results from two independent experiments (solid and hatched bars). (c) Electron microscopy of a cancer cell treated with ten MOI of D24. Four days after infection, numerous viral particles were observed in the cancer cells (left). An area of the cell has been enlarged to show the viral structures (right) function, to reduce the eect of the D24 on the viability of wild-type Rb cells. D-54 MG cells were infected with 100 MOI of an adenoviral vector carrying the exogenous wild-type p21 cDNA or Ad5CMV-pA, and 3 days later were infected with the D24 virus at ten MOI. For cells that had not been infected with Ad5CMV-p21 vector, a total cytopathic eect (74.2+2.9% decrease of viability) was observed 5 days after the infection with D24. In contrast, p21-pretreatment provided partial protection against the D24 adenovirus as re¯ected by a 64.2+4% increase in viability. As was true for the Rb-transfer experiment, growth inhibition (40+1.9%) was apparent 3 days after infection with Ad5CMV-p21. Thus, p21-treated cells showed an overrepresentation in the G1 phase of the cell cycle in comparison with cells treated with the adenovirus control (91.4+0.4% and 75.3+0.9%, respectively).
Treatment with D24 induces entry of cells into S phase and cell death
Flow cytometric analysis of the DNA content of the D24-infected cells showed an accumulation of cells in the S phase by the third day after the infection. Thus, 81+10.1% of D24-infected-U-251 MG cells were in the S phase of the cell cycle versus 10+2.3% of the UV-D24-infected cells. Similar results were observed in D-54 MG cells, and 77.4% and 77.3% of D-24-infectedcells were in S phase (in comparison with 14.5% and 15.3% of the control-infected cells) in two independent experiments. As mentioned above, accumulation of cells in the S phase was also observed in D-24-infected Saos-2 cells. At 7 days after infection, cytopathic eect was widespread. At that moment, the majority of the cells detached from the dish and cellular debris were numerous. However, there was only a small population of cells in the sub-G1 area as assessed by¯ow cytometric analyses. Thus, 7.72+3.8% of D-24-infected -U-251 MG were in the sub-G1 region (versus 1.7+0.1 of control infected cells). The discrepancy between the morphological and¯ow-cytometric data suggested that the virus-mediated cell death was probably due to both cell lysis and apoptosis. Consistent with this, electron microscopy showed necrosis and apoptosis features in the infected cells (data not shown). Interestingly, D24 adenovirus induced cell death even in mutant-p53 cells such as U-251 MG glioma cells (Gomez-Manzano et al., 1996) and Saos-2 (Masuda et al., 1987) . These results indicated that although p53 can cooperate with other viral and cell proteins to enhance adenovirallymediated cell death (Ridgway et al., 1997) , wild-type p53 status was not a major determinant of ecient D24 replication and thus its oncolytic eect.
The D24 adenovirus suppresses tumor growth in vivo To study the antitumor eect of D24 in vivo, the growth of D-54 MG tumors treated with D24 was compared with the growth of tumors those treated with an UVinactivated D24 control virus in a nude mice model. Tumor size was measured periodically until tumors in the control animals achieved the maximum acceptable burden. In the ®rst group of experiments, preestablished D-54 MG xenografts were implanted subcutaneously in nude mice, and when tumors reached at least 5 mm in diameter, tumors were treated with either D24 (n=6) or UV-D24 (n=6) at a dose of 5610 8 PFU per animal every 5 days for a total of ®ve times. D24-treated tumors showed an 83.8% growth inhibition (P50.01, t-student, double sided), with tumor regression in two of the six mice tested. Tumors showing regression have been followed for over 2 months without evidence of regrowth. Hematoxylineosin staining revealed that, after D24 treatment, the remaining tumor mass consisted largely in necrotic tissue. Similar results were obtained in tumors formed after the subcutaneous injection of 10 7 D54 MG cells in the right¯ank of nude mice. These experiments involved the intratumoral injection of 10 9 PFU of either D24 (n=5) or UV-D24 (n=5) every 5 ± 7 days for four doses. With these doses, we observed an 85.7% reduction in the size of treated tumors relative to the size of the control tumors (P50.05, t-student, double sided). As true for the previous group, two of the ®ve D24-treated mice showed tumor regression.
In addition to the multiple injection experiments, we investigated the eect of a single low dose of the D24 adenovirus on tumor growth. Tumors in six mice were injected with 10 7 PFU of the adenovirus control, and tumors in ®ve mice were treated with a similar dose of D24. At the end of the experiment, tumors in the D24-treated group were 66.3% smaller than those in the UV-D24-treated animals (P50.005, t-student, double sided). Despite the low viral dose, all of the D24-treated tumors displayed growth inhibition ( Figure 6 ). None of the mice used in these experiments died before the ending of the experiment. In addition, we did not observe any sign of systemic toxicity including weight loss, abdominal swelling, hunched posture, or diarrhea.
Discussion
Our results indicate that the mutant adenovirus D24 is a potent cytolytic agent against glioma in vitro and in vivo and that the presence of a functionally active Rb protein in quiescent normal cells could halt this cytopathic eect of the mutant D24 adenovirus. Thus the E1A-mutant protein was unable to deregulate the cell cycle and kill non-cycling wild-type Rb cells. Transfer of exogenous Rb to Rb-null cells resulted in resistance to the adenoviral eect in previously virus-sensitive cancer cells, thus con®rming the ability of the wild-type Rb protein to block D24 replication. These results are important for future therapeutic applications of the D24 adenovirus because the existence of a cell cycle-mediated mechanism of resistance to the virus suggests that the anticipated toxicity of an adenovirus expressing a handicapped E1A protein will be limited to the very few, occasionally dividing, reactive glial cells in the adult human brain.
The anti-cancer eect of the adenovirus was potent. In vitro, cell destruction was massive even with very low doses of the virus. In vivo a single local injection of a low dose of the adenovirus resulted in tumor inhibition. Multiple injections produced tumor regression in four of 11 animals. Regression of human gliomas established subcutaneously in mice is a strong indication of the power of the replication-competent strategy. In fact, the inability of current vectors to transduce sucient numbers of tumor cells in vivo may be the major hurdle to successful gene therapy of cancer (Roth and Cristiano, 1997) , especially in cases in which the bystander eect on nontransduced cells is limited. Thus, replication-de®cient adenovirus could transfer an exogenous gene to less than 15% of glioma cells in human patients (Puumalainen et al., 1998) . Several factors, however, favor the use of oncolytic adenoviruses for the treatment of brain tumors. First, gliomas do not metastasize, and therefore an ecient local approach should be enough to cure the disease. Second, every glioma harbors several populations of cells expressing dierent genetic abnormalities (Sidransky et al., 1992; Collins and James, 1993; Furnari et al., 1995; Kyritsis et al., 1996b) . Thus, the spectrum of tumors sensitive to the transfer of a single gene to cancer cells may be limited. Third, replication competent adenoviruses can infect and destroy cancer cells that are arrested in G0. Since gliomas invariably include non-cycling cells, this property is important. Finally, the p16-Rb pathway is abnormal in the majority of gliomas (Hamel et al., 1993; Henson et al., 1994; Hirvonen et al., 1994; Jen et al., 1994; Schmidt et al., 1994; Costello et al., 1996 Costello et al., , 1997 Fueyo et al., 1996b; Kyritsis et al., 1996a; Ueki et al., 1996) , thus making the D24 strategy appropriate for most of these tumors.
A tumor-selective mutant virus seems a promising solution to the problem of gene delivery that is hindering the complete success of conventional gene therapy. Recent advances in the knowledge of how viruses replicate are being used to design tumorselective oncolytic viruses. In gliomas, three kinds of viruses have been shown to be useful in animal models: reoviruses that can replicate selectively in tumors with an activated ras pathway (Coey et al., 1998) ; genetically altered herpes simplex viruses (Martuza et al., 1991; Mineta et al., 1995; Andreanski et al., 1997) , including those that can be activated by the dierent expression of proteins in normal and cancer cells (Chase et al., 1998) ; and mutant adenoviruses that are unable to express the 55-kDa E1B protein and are used to treat p53-mutant tumors (Bischof et al., 1996; Heise et al., 1997; Freytag et al., 1998; Kirn et al., 1998) . Taken together, these reports con®rm the relevance of oncolytic viruses as anti-cancer agents. In all three systems, the goal is the intratumoral spread of the eect and the ability to dierentiate cancer from normal cells. Our own studies on the D24 adenovirus support the tenet that genetically modi®ed adenoviruses that target cellular pathways at key points may have both potent and selective anticancer eects in gliomas. Of further importance is the presence of functional inactivation of the Rb protein in most human cancers (Sherr, 1996) , an observation that suggests that this new therapeutic approach may be applicable to many malignancies.
Materials and methods

In vitro site-directed mutagenesis
The adenovirus D24 was constructed from a modi®ed adenovirus type 5 genome (Microbix Biosystem Inc., Ontario, Canada) as follows. The shuttle plasmid pXC1, which contains the adenovirus 5 sequences from 22 ± 5790 nucleotides, was modi®ed by using phosphorylated mutagenic primers to loop out and delete 24 bases, from 919 to 943, of the adenovirus type 5 corresponding to amino acid residues L, T, C, H, E, A, C, and F of the E1A.
Con®rmation of the D24-E1A by sequencing the genome of the adenovirus A 1-kb fragment of the E1A region of the adenoviral construct was ampli®ed by polymerase chain reaction (PCR) using sense (5'-GATTGGCCACCATGAGACATAT-TATCTGC-3') and antisense (5'-CTGTGGCCATTTAA-CACGCCATGCA-3') primers. Subsequently, 1 mg of concentrated PCR sample was added to 1 ml of each primer (primer dilution 1 : 3 of 0.1 mg/ml) and the volume was brought to 9.5 ml with distilled water. This mixture of PCR fragments and primers was added to a¯uorescein-labeled reaction mix (Applied Biosystems, Foster City, CA, USA) and sequenced in a 373A automated DNA sequencer (Applied Biosystems).
Construction of the D24 by homologous recombination in 293 cells
To generate the mutant adenovirus, the shuttle vectors pXC1-D24, which carries the mutant E1A region of the adenovirus, and pBHG10 (Microbix Biosystem Inc.), which contains the rest of the adenoviral genome except for the E3 region, were cotransfected by liposome-mediated method into 293 cells to allow homologous recombination. To generate infectious virions, individual plaques were isolated and ampli®ed, and the viral titers were determined by plaque assays.
Adenoviruses
Other vectors used included the UV-D24 adenovirus, a D24 virus inactivated by ultraviolet light; Ad5CMV-pA, a E1-deleted adenovirus that carries no exogenous genes (Alemany et al., 1996) ; Ad5CMV-Rb, a E1-deleted adenovirus that carries the Rb cDNA (Fueyo et al., 1998c) ; Ad5CMV-GFP, a vector that can express the green¯uorescent protein (Alemany et al., 1997) ; Ad5CMV-p21, that carries the p21 cDNA (Gomez-Manzano et al., 1997); dl1520, a replication competent adenovirus with a partial deletion of the E1B gene (Barker and Berk, 1987) .
Cell lines and infection conditions
The human glioma cell lines U-251 MG (homozygous deletion of p16 locus, Arap et al., 1995) , U-373 MG (lack of expression of p16 protein, Fueyo et al., 1998b) , and U-87 MG (homozygous deletion of p16 locus, Arap et al., 1995) ; the human sarcoma cell line Saos-2 (lack of wild-type Rb expression, Huang et al., 1998) ; and the normal lung ®broblast line CCD32-Lu were obtained from the American Type Culture Collection (Manassas, VA, USA). The D-54 MG human glioma cells (lack of expression of p16 protein. Fueyo et al., 1996a) were a generous gift from Dr Bigner (Duke University, Durham, NC, USA). The cell lines were infected as described previously (Gomez-Manzano et al., 1996; Fueyo et al., 1998b) .
Western blot analysis
Total cell lysates were prepared by incubating cells for 1 h at 48C in RIPA buer (150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS] , 20 mM EDTA, and 50 mM Tris, pH 7.4) at dierent times after the infection. Thirty micrograms of protein from each sample was then subjected to 7% SDS-Tris-glycine gel electrophoresis. The membrane was blocked with 3% nonfat milk, 0.05% Tween 20, 0.9% NaCl, and 50 mM Tris, pH 7.5, and incubated with the following primary antibodies: rabbit anti-adenovirus-2 E1A protein 13 S-5 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), and mouse anti-human actin IgG (Amersham Corp., Arlington Heights, IL, USA). The secondary antibodies were horse-radish peroxidaseconjugated donkey anti-rabbit IgG (Amersham) and horseradish peroxidase-conjugated donkey anti-mouse IgG (Amersham). The membranes were developed according to Amersham's electrochemi-luminiscence protocol.
Immunoprecipitation
Ten mg of antibody agarose conjugated rabbit anti-adenovirus-2 E1A protein 13 S-5 (Santa Cruz Biotechnology Inc.), was added to 500 mg of total cell proteins from cells infected with D24, dl1520, or Ad5CMV-pA, and incubated at 48C overnight. The pellet was collected by centrifugation, washed with RIPA, and subjected to 7% SDS polyacrylamide gel electrophoresis followed by immunoblotting with goat antihuman Rb C-15 antibody (Santa Cruz Biotechnology, Inc.) (Fueyo et al., 1998c) .
Viability assay
Cells were seeded at 10 5 cells per well in six-well plates and allowed to grow for 20 h. Cells were infected with D24, Ad5CMV-pA, Ad5CMV-Rb, or UV-D24 at the indicated MOI. After 7 ± 14 days of incubation the cell monolayers were ®xed with methanol and stained with 0.2% crystal violet. The experiment was performed three times for each cell line. Trypan blue experiments were performed as described elsewhere (Fueyo et al., 1998b) .
Flow cytometric analyses
These assays were performed as described elsewhere (GomezManzano et al., 1996; Fueyo et al., 1998c) .
Transfer of exogenous wild-type Rb or p21
Characterization of the Rb-and p21-adenovirus and its infection into cells were described elsewhere (GomezManzano et al., 1997; Fueyo et al., 1998c) .
Infectivity experiments in normal cells
CCD32-Lu lung ®broblasts were infected with 10 ± 100 MOI of the Ad5CMV-GFP; and 3 days later, the cells were examined in terms of both interference and¯uorescent contrast. The percentage of infected cells was determined by counting the number of green¯uorescent cells among 500 examined cells.
Viral replication experiments
Viral production was quanti®ed by plaque assay. Six days after infection, cells were scraped into culture medium and lysed by three cycles of freezing and thawing. Cell lysates were clari®ed by centrifugation and the supernatant was serially diluted in medium for the infection of 293 cells in 6-well dishes. After 1 h of incubation at 378C, the infected cells were overlaid with 3 ml of 1.25% SeaPlaque agarose (FMC, Rockland, ME, USA) in DMEM/F12 (10% fetal bovine serum). Additional agarose was added to each dish 4 days later. Plaques were visualized at 7 days after infection.
Electronic microscopy
Four days after infection, pellets from U-251 MG cells infected with UV-D24, or D24 were ®xed in 2% glutaralde- hyde and post-®xed for 1 h in 1% osmium tetroxide. Samples were counterstained with uranyl acetate and lead citrate and examined under a transmission electron microscope (GomezManzano et al., 1996) Animal studies
The animal studies were carried out at the animal facility of The University of Texas M.D. Anderson Cancer Center in accordance with institutional guidelines. Mice were acclimated and caged in groups of ®ve or less. All mice were fed animal chow and water ad libitum. Animals were anesthetized with methoxy¯urane before all procedures and were observed until fully recovered from the eect of the anesthesic. Pieces of approximately 3 mm in diameter of D-54 MG preestablished tumors, or 10 7 D-54MG parental cells were inoculated subcutaneously into the right¯anks of 6-to 8-week-old athymic BALB/c-nu/nu (nude) mice (Harlan Sprague-Dawley Co., Houston, TX, USA). When tumors reached at least 5 mm in diameter, they were injected with either D24 or UV-D24 at one of the indicated doses. The largest (a) and smallest (b) diameters of each tumor were measured, and tumor volume was calculated using the formula a6b 2 60.4 (Attia and Weiss, 1996) . When the tumors had reached the maximum acceptable size, the mice were killed, and their tumors were excised and analysed by histological ®xation and staining with hematoxylin and eosin. Each experiment was performed separately on at least ®ve dierent animals from each group. Tumor responses to each treatment were compared by the two-tailed t-student test.
